Skip to main content

Highlights

  1. 1
    Children (Basel, Switzerland) · 2022
    PMID: 35884027PMCID: PMC9320728DOIFirst author13 citations
  2. 2
    Clinical obstetrics and gynecology · 2022
    PMID: 35045036PMCID: PMC8767917DOIFirst author5 citations
  3. 3
    JAMA network open · 2026
    PMID: 41697699PMCID: PMC12910395DOIFirst author4 citations

Publications

32 publications

Funding

1 grant
Completed grants (1)
  • Co-I
    Immune Cells and Secretory Pathways Leading to Human Systemic Autoimmunity
    National Institute of Allergy and Infectious Diseases · 2020–2024
    U19AI144301-02S1

Clinical research

6 studies

Active

4 studies
  • PI
    Characterization of nasopharyngeal immune responses and microbiome profiles in children with respiratory viral co-infections
    Weill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2026)
  • PI
    Retrospective study of vaccine uptake and outcomes of vaccine-preventable infections in pediatrics
    Weill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2024)
  • PI
    Reducing unnecessary urine cultures through reflexive urine culture testing in children
    Columbia University · OPEN TO ACCRUAL (as of 2024)
  • PI
    Pocapavir for emergency compassionate use in a patient with enteroviral sepsis and endocarditis
    Weill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2019)
Completed & closed trials (2)
  • PI
    Outcomes of Implementing Blood Culture Best Practices in the Management of Immunocompromised Pediatric Patients
    Montefiore Medical Center · CLOSED TO ACCRUAL (as of 2025)
  • PI
    An Observational Cohort Study to Determine Late Outcomes and Immunological Responses After Infection With SARS-CoV-2 in Children With and Without Multisystem Inflammatory Syndrome (MIS-C)
    National Institute of Allergy & Infectious Diseases · CLOSED TO ACCRUAL (as of 2022)
    Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2); Multisystem Inflammatory Syndrome in Children (MIS-C); Coronavirus Disease 2019 (COVID-19)
    NCT04588363

News mentions

  • What to Know About the COVID-19 Vaccine and Young Kids
    November 12, 2021

    About 28 million children became eligible for the COVID-19 vaccine after the Food and Drug Administration (FDA) and Centers for Disease Control and Prevention (CDC) approved and created guidelines for children ages 5 to 11 to receive the Pfizer/BioNTech COVID-19 vaccine. But as the vaccine rollout begins for younger kids, many parents may have questions.